Arcutis Biotherapeutics (NASDAQ: ARQT) insider sale notice: 3,687 shares

Rhea-AI Filing Summary

Arcutis Biotherapeutics reports a proposed sale of common stock. The filing lists 3,687 shares of common stock described under "Securities To Be Sold" with an effective date of 03/01/2026. The excerpt also shows a prior sale by Todd Edwards of 2,052 common shares on 02/02/2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	3687	92846.4	122492192	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2026	Restricted Stock Vest	Arcutis Biotherapeutics Inc			3687	03/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd Edwards 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	02/02/2026	2052	52323

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arcutis Biotherapeutics' Form 144 show (ARQT)?

The Form 144 lists a proposed sale of 3,687 shares of common stock with an effective date of 03/01/2026. It also records a prior sale of 2,052 common shares by Todd Edwards on 02/02/2026.

Who reported recent sales in the ARQT filing?

The excerpt identifies Todd Edwards as the reporting party for a sale of 2,052 common shares on 02/02/2026. The filing separately lists a proposed sale of 3,687 shares tied to 03/01/2026.

Are the securities in the Form 144 restricted or unrestricted (ARQT)?

The filing entry labeled "Restricted Stock Vest" is associated with the 3,687 shares and the date 03/01/2026, indicating the shares are described as restricted in the excerpt and tied to a vesting event.

Does the Form 144 state how proceeds will be used (ARQT)?

The provided excerpt does not include any language on the use of proceeds. The filing focuses on share counts and dates: 3,687 proposed shares (03/01/2026) and a prior sale of 2,052 shares (02/02/2026).

What markets or broker information appear in the ARQT excerpt?

The excerpt references NASDAQ and shows a broker address for Merrill Lynch at 8890 Lyra Drive, Columbus, OH. It also ties the securities entries to the common stock of the company on the dates shown.